Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy

Shengnan Ren†, Xiaofei Zhu†, Anyu Zhang†, Danni Li, Changjing Zuo* and Huojun Zhang*

Abstract

Background: 18F-FDG PET/CT metabolic parameters have been applied as prognostic factors in multi-malignancies. However, the role in locally advanced pancreatic cancer (LAPC) was not confirmed. In this study, we investigated the prognostic value of 18F-FDG PET/CT metabolic parameters in LAPC patients treated with stereotactic body radiation therapy (SBRT).

Methods: Seventy three LAPC patients who received SBRT therapy and pre-treatment 18F-FDG PET/CT imaging from January 2012 to January 2016 were included in this retrospective study. The study aim was to evaluate the relationship between metabolic parameters with clinical factors, and the value of metabolic parameters in the prognosis of LAPC. The median of parameters was set as the cut-off value for statistical analysis. Univariate survival analysis was performed by the Kaplan Meier method and log-rank test, and multivariate analysis was carried out by a Cox proportional hazards model.

Results: Patients with lymph node metastasis or longer tumor diameters were associated with higher TLG (P < 0.05). Univariate analysis showed MTV, TLG, radiotherapy dose and chemotherapy were significantly associated with disease progression-free survival (PFS) and overall survival (OS) (P < 0.05). Lymph node metastasis and tumor longest diameter were associated with OS. Multivariate analysis demonstrated TLG, radiotherapy dose, and chemotherapy were independent factors of PFS and OS (HR: 2.307, 0.591, 0.572 and 2.145, 0.480, 0.471, P < 0.05).

Conclusions: TLG was found to be the independent prognostic factor of OS and PFS. Among clinical factors, radiotherapy dose and chemotherapy were independent prognostic factors of OS and PFS.

Keywords: Locally advanced pancreatic cancer, Prognosis, 18F-FDG PET/CT, Stereotactic body radiotherapy, Cyberknife radiosurgery
Background
Pancreatic cancer is one of the malignancies with extremely poor prognosis. Its one-year survival rate is about 15%, and less than 5% of pancreatic patients survived more than 5 years [1]. Currently, surgery remains to be the only cure for pancreatic cancer. However, because of the hidden location, and lack of typical symptoms in the early stages, only about 20% of patients showed surgical indications at the time of diagnosis. About 20–40% of patients are diagnosed with locally advanced pancreatic cancers (LAPC), whose median survival period was 6–14 months. Of the 40–45% of pancreatic cancer patients who present with distant metastases, the median survival time was only 3–6 months [2].

According to the American Society of Clinical Oncology (ASCO) guidelines, the recommended therapies for LAPC includes mono-chemotherapy, multi-agent chemotherapy, and chemoradiotherapy (CRT) [3]. Cyberknife, a newly developed Stereotactic body radiation therapy (SBRT) device, has been widely used in cancer treatment. The new technology is a precise radiotherapy mode guided by real-time imaging, which means a higher dose of radiation in the target areas and fewer side effects. Patients who received SBRT barely showed serious adverse reactions in relevant studies [4]. Moreover, 86% of SBRT treated patients illustrated obvious relief in pain, and 78% of which showed disease-controlling effect. In phase III clinical trial [5], SBRT was described as a potential standard treatment for pancreatic cancer under certain circumstances.

Most LAPC patients died of local recurrence or post-treatment metastasis. The low survival rate and non-durable treatment responses make early-stage prognostic evaluation particularly important for LAPC patients. \(^{18}\)F-FDG PET/CT is a combination of functional imaging and anatomical imaging, which has been clinically applied in diagnosis, staging, recurrence, and treatment efficacy evaluation of multiple malignancies [6,7]. Research performed by Schellenberg et al. [8] showed that the pre-treatment \(\text{SUV}_{\text{max}}\) was associated with the overall survival (OS) and progression-free survival (PFS) of pancreatic cancer patients. In recent studies, another two \(^{18}\)F-FDG PET/CT volumetric metabolic parameters, tumor metabolic volume (MTV) and total lesion glycolysis (TLG), showed greater value in the evaluation of pancreatic cancer prognosis than \(\text{SUV}_{\text{max}}\) [9,10]. However, the limited numbers of the current studies about \(^{18}\)F-FDG PET/CT parameters in LAPC prognosis failed to show any consistent result. Moreover, studies on \(^{18}\)F-FDG PET/CT metabolic parameters in prognostic value of LAPC treated with SBRT by Cyberknife are rare. In our previous study [11], \(^{18}\)F-FDG PET/CT metabolic parameters were tested for the prognostic value among 23 LAPC patients who received chemotherapy as well as SBRT. In this study, besides the patients received both chemotherapy and SBRT, we expanded the criteria to include the LAPC patients treated with SBRT only. In order to further discuss the individual-based prognosis assessment for LAPC patients.

Methods
All methods included in this study were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the Institutional Review Board of Changhai Hospital.

Patients
We retrospectively analyzed patients who underwent \(^{18}\)F-FDG PET/CT scan and received SBRT at our institution between January 2012 to January 2016. Informed consent was obtained from all subjects.

Inclusion criteria
Firstly, pathologically confirmed as pancreatic cancer. Secondly, Underwent \(^{18}\)F-FDG PET/CT scan within 2 weeks before SBRT treatment.

Exclusion criteria
Firstly, distant metastasis found by \(^{18}\)F-FDG PET/CT. Secondly, presence of cocurrent malignancies other than pancreatic cancer. Thirdly, previous history of anti-tumor treatment at the pancreas site. Fourthly, Deaths caused by diseases other than pancreatic cancer during follow-ups. Lastly, patients who were not willing to obey the treatment plan or examination schedule during follow-ups.

In the end, medical data of 73 patients was collected and retrospectively analyzed.

\(^{18}\)F-FDG PET/CT
All scans were performed before treatment, patients were injected with \(^{18}\)F-FDG (radiochemical purity ≥95%, Shanghai Atomic Kexing Pharmaceutical Co., Ltd.) at a dose of 3.70–5.55 MBq/kg. At least 6 h of fasting was applied to all patients prior to scanning, and the blood glucose level was reported below 11.1 mmol/L. All acquisition was performed on a Biograph tripoint 64-layer 52-ring HD PET/CT scanner (Siemens, Germany), 45–60 min after the injection of \(^{18}\)F-FDG. PET images were performed on 5–6 bed positions with 2.5 min per bed position from mid-skull to mid-thigh. As for CT scanning parameters, slice thickness was 3 mm, acquisition time was 18.67 to 21.93 s, under 170 mA and 120 kV voltage.

Analysis of \(^{18}\)F-FDG PET/CT images
The three-dimensional and fusion images were reconstructed by using the ordered subset expectation maximization (OSEM) and the Multimodality multimode workstation, respectively. Two experienced nuclear medicine physicians, who were both blinded to the outcomes, reviewed all images. And spherical regions of interest were circled around the identified
lesion tissues afterward. \( \text{SUV}_{\text{max}} \), \( \text{SUV}_{\text{mean}} \), MTV, and TLG were offered by the TrueD system automatically. The ceCT or MRI images were used to help differentiate inflammatory activity from tumor tissue if necessary. MTV was evaluated at the baseline of 40% of \( \text{SUV}_{\text{max}} \). The longest tumor diameter was measured on CT images. Meanwhile, the lymph nodes with a short axis diameter greater than 1 cm were considered as lymph node metastases.

Therapies

**Stereotactic body radiation therapy delivery**

Radiation therapies were carried out by the Cyberknife® (Accuray Incorporated, Sunnyvale, United States), an image-guided frameless treatment system. The vertebral tracking technology was used to provide real-time imaging, which replaced the motion detection by gold fiducials implantation. All patients underwent a ceCT or MRI scan before radiation therapy for treatment boundary assessment. RADIOTHERAPY was defined as the CT evidenced total tumor range. The planning target volume (PTV) included the whole radiotherapy area with extended margins (2 to 3 mm) in X, Y, and Z axis. The routine dose for single irradiation was 6–8 Gy, 4 to 8 repeats for a course. And the treatment parameters were adjustable between different individual situations.

**Chemotherapy devilry**

Fifty LAPC patients received single SBRT treatment because of the chemotherapy intolerance. 23 patients received chemotherapy and SBRT combination therapy. Among which, 13 patients received gemcitabine-based chemotherapy, 9 patients received S-1 based chemotherapy, and 1 patient received gemcitabine -S-1 multi-agent chemotherapy.

**Follow-ups and statistical analysis**

Patients were followed up by telephone or through the clinic. OS and PFS were used as prognostic indicators. OS refers to the time duration between the day therapy begun to the day of disease-related death or last visit. PFS was defined as the period from the completion of treatment to disease progression, including local progression distant metastasis, or any causes of death or the last follow-up in the case of no progression. Disease progression was evaluated by RECIST criteria (v1.1). Patients included were required to take enhanced contrast CT and MRI every 2 to 3 months during follow-up.

Statistical analysis was performed using SPSS version 22 statistical software (Portsmouth, UK). Mann-Whitney U or Kruskal-Wallis H test was applied for the correlation between clinical factors and metabolic parameters. All continuous variables were presented as median value M (P25, P75). For survival analysis, patients were put into two groups (high-value group and low-value group) based on the medium value of continuous variables. Afterward, all data were analyzed by the Kaplan-Meier methods for the purpose of univariate analysis, and then significant variables were included in the Multivariate step-wise forward Wald–Cox regression. \( P \) value < 0.05 was considered as statistically significant.

**Results**

**Relationship between clinical factors and metabolic parameters**

The median values of \( \text{SUV}_{\text{max}}, \text{SUV}_{\text{mean}}, \text{MTV} \) and TLG in 73 LAPC patients were 6.9 (P25: 5.85, P75: 9.85), 4.0 (P25: 3.2, P75: 5.6), 12.2 (P25: 7.0, P75: 22.5) cm³, and 49.3 (P25: 31.6, P75: 86.0) g, respectively. \( \text{SUV}_{\text{max}}, \text{SUV}_{\text{mean}} \) and TLG of patients with lymph node metastasis were 8.6 (P25: 5.9, P75: 11.2), 4.9 (P25: 3.3, P75: 5.7), and 67.8 (P25: 37.9, P75: 117.1) g, respectively, which were significantly higher than those without lymph node metastasis (6.7 (P25: 5.9, P75: 11.2), 3.7 (P25: 3.1, P75: 4.4), and 45.6 (P25: 27.9, P75: 64.4) g, respectively \( (P = 0.029, 0.048 \) and 0.007, respectively). Moreover, a longer tumor diameter was associated with higher TLG \( (P = 0.035) \). No significant differences were found between MTV and clinical factors \( (P > 0.05, \text{Table 1}) \).

**Patient characteristics**

Seventy three LAPC patients (46 males, 27 females) from January 2012 to January 2016 were enrolled in this study, the basic characteristics and pre-treatment conditions were summarized in Table 2. The median follow-up duration was 37 months (range: 12–55 months). For OS, there were 6 cases with censored data, including 2 patients lost follow-ups and 4 patients who were alive. And the rate of lost follow-ups was 2.7%. The median PFS time was 9.7 months \( (95\% \text{ CI}: 9.1–10.3) \), only one case presented with censored data in PFS, who showed no evidence of disease progression by the end of follow-up. The 1-year and 2 years PFS rate was 30.1 and 41.1%, respectively. Meanwhile, the median OS period was 14.4 months \( (95\% \text{ CI}: 13.3–15.5) \). The 1-year and 2-year OS rates were 78.1 and 11.2%, respectively.

**Survival analysis and univariate analysis**

The log-rank test was used to analyze metabolic parameters, including MTV and TLG \( \text{(Fig. 1, Table 3)} \), and we found MTV and TLG were prognostic factors of OS and PFS. The median overall survival time was 15.6 months \( (95\% \text{ CI}: 14.1–17.2) \) and 13.2 months \( (95\% \text{ CI}: 11.6–14.8) \) months for patients with MTV \( \leq 12.2 \) and MTV > 12.2 respectively \( (P = 0.036, \text{HR}:1.669,95\% \text{ CI}: 1.025–2.716) \). The median overall survival time was 15.9 months \( (95\% \text{ CI}: 14.9–16.9) \) for patients with TLG \( \leq 49.3 \), and 12.9 months \( (95\% \text{ CI}: 12.1–13.7) \) for patients with
### Table 1 Correlation between Clinical Factors and SUVmax, SUVmean, MTV and TLG in 73 LAPC Patients

| Clinical Factors | Cases | SUVmax     | z Value or $\chi^2$ Value | P Value | SUVmean     | z Value or $\chi^2$ Value | P Value |
|------------------|-------|------------|--------------------------|---------|------------|--------------------------|---------|
|                  |       | M (P25, P75) |                |         | M (P25, P75) |                |         |
| Age (yrs)        |       |            | −0.387                  | 0.699   | −0.392     | 0.695        |
| ≤68              | 38    | 7.0 (6.1, 9.7) |                |         | 4.1 (3.4, 5.7) |                |         |
| >68              | 35    | 6.6 (5.3, 10.1) |                |         | 3.8 (3.0, 5.5) |                |         |
| Presence of DM   |       | −0.533     | 0.594                  |         | −0.232     | 0.816        |
| No               | 58    | 6.9 (5.9, 10.0) |                |         | 4.0 (3.2, 5.7) |                |         |
| Yes              | 15    | 6.8 (5.8, 8.5) |                |         | 4.0 (3.0, 5.3) |                |         |
| ECOG             |       | 0.838a     | 0.658                  |         | 1.742a     | 0.418        |
| 0                | 13    | 6.7 (6.4, 9.9) |                |         | 4.0 (3.5, 5.4) |                |         |
| 1                | 32    | 7.1 (5.5, 11.3) |              |         | 4.3 (2.9, 6.7) |                |         |
| 2                | 28    | 6.6 (5.2, 9.1) |                |         | 3.7 (3.0, 5.2) |                |         |
| N Stage          |       | −2.184     | 0.029                  |         | −1.974     | 0.048        |
| 0                | 40    | 6.7 (5.6, 8.1) |                |         | 3.7 (3.1, 4.4) |                |         |
| 1                | 33    | 8.6 (5.9, 11.2) |               |         | 4.9 (3.3, 6.5) |                |         |
| Position         |       | −0.709     | 0.478                  |         | −0.746     | 0.456        |
| Head             | 51    | 6.8 (6.0, 10.2) |               |         | 4.1 (3.4, 5.5) |                |         |
| Body/ Tail       | 22    | 7.0 (5.2, 9.6) |                |         | 3.8 (3.0, 5.7) |                |         |
| The longest diameter (cm) | | −1.353     | 0.176                  |         | −1.054     | 0.292        |
| ≤3.7             | 40    | 6.7 (5.8, 8.4) |                |         | 3.9 (3.1, 5.1) |                |         |
| >3.7             | 33    | 7.3 (6.0, 11.1) |               |         | 4.2 (3.1, 6.6) |                |         |
| CA 19–9 (ng/mL)  |       | −0.590     | 0.555                  |         | −0.497     | 0.619        |
| ≤321.6           | 37    | 6.7 (5.7, 9.6) |                |         | 4.0 (3.0, 5.4) |                |         |
| >321.6           | 36    | 7.1 (5.8, 10.0) |               |         | 4.1 (3.3, 5.7) |                |         |
| Clinical Factors | Cases | MTV (cm$^3$) |                |         | TLG (g)    |                |         |
|                  |       | M (P25, P75) | z Value or $\chi^2$ Value | P Value | M (P25, P75) | z Value or $\chi^2$ Value | P Value |
| Age (yrs)        |       |            | −0.961                  | 0.337   | −0.939     | 0.348        |
| ≤68              | 38    | 11.3 (6.5, 19.8) |              |         | 48.2 (29.6, 75.4) |                |         |
| >68              | 35    | 13.2 (7.3, 27.1) |               |         | 58.1 (33.9, 98.4) |                |         |
| Presence of DM   |       | −0.608     | 0.543                  |         | 0.000      | 1.000        |
| No               | 58    | 11.8 (7.3, 20.0) |                |         | 49.0 (34.2, 85.2) |                |         |
| Yes              | 15    | 15.9 (5.2, 35.5) |                |         | 62.2 (25.4, 146.3) |                |         |
| ECOG             |       | 0.331b     | 0.847                  |         | 0.063b     | 0.969        |
| 0                | 13    | 12.2 (7.0, 20.5) |                |         | 48.7 (32.3, 83.5) |                |         |
| 1                | 32    | 10.5 (5.6, 23.7) |                |         | 51.0 (29.9, 88.9) |                |         |
| 2                | 28    | 12.6 (9.2, 25.9) |                |         | 49.4 (34.0, 93.9) |                |         |
| N Stage          |       | −1.336     | 0.182                  |         | −2.682     | 0.007        |
| 0                | 40    | 12.1 (6.3, 15.7) |                |         | 45.6 (27.9, 64.4) |                |         |
| 1                | 33    | 13.9 (7.0, 35.6) |                |         | 67.8 (37.9, 117.1) |                |         |
| Position         |       | −1.455     | 0.146                  |         | −1.353     | 0.176        |
| Head             | 51    | 11.7 (6.7, 5.9) |                |         | 46.8 (28.6, 82.1) |                |         |
| Body/ Tail       | 22    | 20.2 (7.8, 28.5) |                |         | 61.1 (39.7, 99.1) |                |         |
| The longest diameter (cm) | | −1.596     | 0.110                  |         | −2.111     | 0.035        |
| ≤3.7             | 40    | 10.0 (5.6, 18.9) |                |         | 41.7 (26.0, 77.5) |                |         |
Table 1 Correlation between Clinical Factors and SUVmax, SUVmean, MTV and TLG in 73 LAPC Patients (Continued)

| Clinical Factors | Cases | SUVmax (M (P25, P75)) | z Value or χ² Value | P Value | SUVmean (M (P25, P75)) | z Value or χ² Value | P Value |
|------------------|-------|-----------------------|---------------------|---------|------------------------|---------------------|---------|
| > 3.7            | 33    | 13.9 (8.4, 24.2)      | −0.083              | 0.934   | 64.7 (40.0, 91.3)      | −0.535              | 0.593   |
| CA 19–9 (ng/mL)  |       |                       |                     |         |                        |                     |         |
| ≤ 321.6          | 37    | 12.6 (7.5, 17.9)      | −0.632              | 0.526   | 48.7 (32.2, 80.6)      | −0.280              | 0.782   |
| > 321.6          | 36    | 10.5 (6.4, 25.2)      | −0.632              | 0.526   | 55.4 (30.7, 92.5)      | −0.280              | 0.782   |

LAPC locally advanced pancreatic cancer; SUV standardized uptake value; MTV metabolic tumor volume; TLG total lesion glycolysis; DM diabetes mellitus; ECOG Eastern Cooperative Oncology Group

*+, P < 0.05

Table 2 Patient characteristics

| Characteristics | Total (n = 73) |
|-----------------|---------------|
| Gender          |               |
| Male            | 46            |
| Female          | 27            |
| Age (yrs), Median (range) | 68 (42–84) |
| N Stage         |               |
| N₀              | 40            |
| N₁              | 33            |
| Tumor Location  |               |
| Head            | 51            |
| Body/Tail       | 22            |
| Longest Diameter of Tumor (cm), Median (range) | 3.7 (1.0–7.5) |
| Serum CA19–9 Level (ng/mL), Median (range) | 321.6 (2.0–1200.0) |
| Present of DM   | 15            |
| ECOG Score      |               |
| 0               | 13            |
| 1               | 32            |
| 2               | 28            |

DM diabetes mellitus; ECOG Eastern Cooperative Oncology Group

TLG > 49.3, respectively (P = 0.001, HR: 2.320,95% CI: 1.413–3.809).

The median PFS time of patients with MTV ≤ 12.2 and MTV > 12.2 was 10.4 (95% CI: 9.1–11.7) months and 8.4 (95% CI: 6.5–10.3) months (P = 0.048, HR: 1.601, 95% CI: 0.998–2.567), respectively. The median PFS time of patients with TLG ≤ 49.3 and TLG > 49.3 was 11.7 (95% CI: 8.0–15.4) months and 7.9 (95% CI: 7.0–8.9) months, respectively (P = 0.001, HR: 2.424, 95% CI: 1.495–3.939).

As for clinical factors, Lymph node metastasis, longest diameter of tumor, radiotherapy dose and chemotherapy were significant OS-related prognostic factors (P = 0.029, 0.045, 0.001 and 0.006, respectively). Patients with lymph node metastases, longer tumor diameters or lower radiotherapy dose tended to have shorter OS. Meanwhile, LAPC patients treated without chemotherapy also showed a shorter OS duration. In addition, radiotherapy dose and chemotherapy were significantly associated with PFS (P = 0.002 and 0.030, respectively). LAPC patients received higher radiotherapy dose or combined with chemotherapy demonstrated a longer PFS time (Table 3).

Multivariate analysis of prognostic factor

Multivariate analysis performed by Cox proportional hazards models showed that TLG, radiotherapy dose, and chemotherapy were independent prognostic factors for OS and PFS.

The hazard ratio (HR) of TLG, radiotherapy dose and chemotherapy upon OS was 2.145 (P = 0.003, 95% CI: 1.292–3.560), 0.480 (P = 0.004, 95% CI: 0.289–0.796) and 0.471 (P = 0.010, 95% CI: 0.267–0.833), respectively. The HR of TLG, radiotherapy dose and chemotherapy upon PFS was 2.307 (P = 0.001, 95% CI: 1.406–3.787), 0.591 (P = 0.033, 95% CI: 0.364–0.960) and 0.572 (P = 0.040, 95% CI: 0.335–0.976), respectively. All P < 0.05 (Table 4).

Among clinical factors, radiotherapy dose and chemotherapy were found as indepent prognostic factors. Mann-Whitney U test was used verify the distribution difference of clinical factors between two groups of patients with or without chemotherapy, and between two groups with high or low radiotherapy dose (Table 5). The statistical results indicated that there was no statistical difference in the distribution of clinical factors between the chemotherapy group (23 cases) and the non-chemotherapy group (50 cases). The negative results also showed between the low radiotherapy dose group (37 cases) and the high radiotherapy dose group (36 cases). According to statistical data, the selection bias possibly caused by retrospective study could be reduced.

Typical cases of PET/CT images were presented in Figs. 2 and 3.

Discussion

In this study, among four 18F-FDG PET/CT metabolic parameters, TLG showed a significant correlation with lymph node metastasis and the longest tumor diameter.
Univariate analysis showed MTV, TLG, radiotherapy dose, and chemotherapy as significant prognostic factors for OS and PFS. However, lymph node metastasis and the longest diameter of the tumor were prognostic factors only for OS. In the Multivariate analysis, for LAPC patients treated with SBRT by Cyberknife, TLG, radiotherapy dose and chemotherapy were demonstrated as the independent prognostic factors for OS and PFS.

Although current research on the LAPC potential prognostic markers has reached the molecular level, such as tissue biomarkers, epigenetic markers and blood markers, including circulating tumors, few of them have been clinically recognized [12–14]. PET/CT is a technique integrating functional imaging together with anatomy imaging, which has been widely applied in the prognosis of various malignant tumors. SUV$_{\text{max}}$, as the most commonly used semi-quantitative index in FDG PET/CT, is still controversial in LAPC prognosis assessment. Several previous studies confirmed the prognostic role of SUV$_{\text{max}}$ in LAPC and suggested that the higher the pre-treatment SUV$_{\text{max}}$ value of the primary lesions, the poorer the prognosis [8, 15]. Schellenberg et al. [8] also found in a univariate analysis that the metabolic burden of the primary pancreatic tumor (similar conception to MTV) was prognostically related, but only SUV$_{\text{max}}$ was an independent prognostic factor. However, SUV$_{\text{max}}$ only represents the highest metabolic

![Fig. 1](image.png)

**Fig. 1** Kaplan-Meier univariate analysis of OS according to MTV (a) and TLG (b), PFS according to MTV (c) and TLG (d).
## Table 3 Univariate Analysis of Prognostic Factors for 73 LAPC patients

| Factors                  | Cases | OS | PFS |
|--------------------------|-------|----|-----|
|                          | Cases | Median OS (Month) | 95% CI | y2 Value | P Value | Cases | Median PFS (Month) | 95% CI | y2 Value | P Value |
| Gender                   | 0.010 | 0.918 | 0.342 | 0.559 |
| Male                     | 46    | 44  | 14.6 | 12.9–16.3 | 45 | 9.8 | 9.1–10.5 |
| Female                   | 27    | 23  | 13.8 | 12.1–15.5 | 27 | 9.4 | 8.0–10.8 |
| Age (yrs)                | 2.284 | 0.131 | 2.041 | 0.153 |
| ≤68                      | 38    | 34  | 15.3 | 13.8–16.8 | 37 | 9.4 | 8.2–10.6 |
| >68                      | 35    | 33  | 13.6 | 12.1–15.1 | 35 | 10.0 | 8.3–11.7 |
| Presence of DM           | 0.308 | 0.579 | 0.683 | 0.409 |
| No                       | 58    | 54  | 13.8 | 12.1–15.5 | 57 | 9.6 | 8.7–10.5 |
| Yes                      | 15    | 13  | 14.6 | 13.7–15.5 | 15 | 10.8 | 8.0–13.6 |
| ECOG                     | 0.485 | 0.785 | 0.006 | 0.997 |
| 0                        | 13    | 12  | 13.2 | 9.8–16.6 | 12 | 9.8 | 7.1–12.5 |
| 1                        | 32    | 30  | 13.8 | 13.0–14.6 | 32 | 9.6 | 8.8–10.4 |
| 2                        | 28    | 25  | 14.7 | 13.0–16.4 | 28 | 9.4 | 8.4–10.3 |
| N Stage                  | 4.748 | 0.029* | 0.267 | 0.132 |
| 0                        | 40    | 35  | 15.1 | 13.1–17.1 | 40 | 9.9 | 6.8–13.0 |
| 1                        | 33    | 32  | 13.2 | 12.2–14.2 | 32 | 9.2 | 7.9–10.6 |
| Tumor Location           | 0.029 | 0.864 | 0.000 | 0.990 |
| Head                     | 51    | 46  | 14.6 | 13.1–16.1 | 50 | 9.8 | 9.3–10.3 |
| Body/Tail                | 22    | 21  | 14.0 | 12.4–15.6 | 22 | 8.8 | 7.3–10.3 |
| Longest Diameter (cm)    | 4.010 | 0.045* | 2.196 | 0.138 |
| ≤3.7                     | 40    | 35  | 14.8 | 13.7–15.9 | 40 | 10.0 | 8.6–11.4 |
| >3.7                     | 33    | 32  | 13.2 | 11.9–14.6 | 32 | 9.1 | 7.9–10.3 |
| CA19–9 (ng/mL)           | 3.391 | 0.066 | 3.126 | 0.077 |
| ≤321.6                   | 37    | 32  | 15.3 | 14.1–16.5 | 36 | 10.4 | 9.1–11.7 |
| >321.6                   | 38    | 35  | 13.2 | 11.9–14.5 | 36 | 8.8 | 7.2–10.4 |
| Radiotherapy Dose (Gy)   | 13.907 | <0.001* | 9.834 | 0.002* |
| ≤37.2                    | 37    | 34  | 12.2 | 11.3–13.2 | 36 | 7.9 | 7.0–8.9 |
| >37.2                    | 36    | 33  | 16.6 | 15.4–17.8 | 36 | 11.3 | 7.8–14.8 |
| Chemotherapy             | 7.603 | 0.006* | 4.690 | 0.030* |
| No                       | 50    | 49  | 13.8 | 12.7–15.0 | 49 | 9.5 | 8.5–10.5 |
| Yes                      | 23    | 18  | 16.7 | 11.5–21.9 | 23 | 11.3 | 4.9–17.7 |
| SUVmax                   | 0.747 | 0.387 | 0.205 | 0.651 |
| ≤6.9                     | 38    | 34  | 14.7 | 13.3–16.1 | 38 | 9.8 | 8.9–10.7 |
| >6.9                     | 35    | 33  | 13.7 | 12.3–15.1 | 34 | 9.5 | 8.3–10.7 |
| SUVmean                  | 0.310 | 0.578 | 0.074 | 0.785 |
| ≤4.0                     | 38    | 34  | 14.7 | 13.3–16.1 | 38 | 9.8 | 8.9–10.7 |
| >4.0                     | 35    | 33  | 13.7 | 12.3–15.1 | 34 | 9.5 | 8.3–10.7 |
| MTV (cm³)                | 4.401 | 0.036* | 3.913 | 0.048* |
| ≤12.2                    | 37    | 32  | 15.6 | 14.1–17.2 | 36 | 10.4 | 9.1–11.7 |
| >12.2                    | 36    | 35  | 13.2 | 11.6–14.8 | 36 | 8.4 | 6.5–10.3 |
| TLG (g)                  | 11.843 | 0.001* | 13.777 | <0.001* |
| ≤49.3                    | 36    | 31  | 15.9 | 14.9–16.9 | 35 | 11.7 | 8.0–15.4 |
| >49.3                    | 37    | 36  | 12.9 | 12.1–13.7 | 37 | 7.9 | 7.0–8.9 |

LAPC: locally advanced pancreatic cancer; OS: overall survival; PFS: progression-free survival; DM: diabetes mellitus; ECOG: Eastern Cooperative Oncology Group; SUV: standard uptake value; MTV: metabolic tumour volume; TLG: total lesion glycolysis

*: P < 0.05
activity within tumor lesions and is easily affected by noise. At the same time, SUV\textsubscript{mean} is calculated from the average SUV value of the entire tumor, normally varies between different operators. Moreover, SUV\textsubscript{mean} can not reflect the internal metabolic characteristics of tumor. A recent study carried out by Dholakia et al. [16] found that SUV\textsubscript{max} was not an independent prognostic factor for LAPC, while MTV and TLG were proved to be independent factors in LAPC prognostic value. LAPC patients with higher MTV or TLG led to poor prognosis. Similar to our study, in which SUV\textsubscript{max} and SUV\textsubscript{mean} were found not significantly associated with PFS or OS.

MTV refers to the volume of tumor tissue, whose FDG uptake exceeds a certain threshold (40% of SUV\textsubscript{max} in this study). TLG represents the metabolic activity and metabolic volume of the tumor tissue. Compared to SUV, MTV and TLG have advantages in reflecting the tumor metabolic burden. Thus, MTV and TLG could provide a more accurate prognostic value. In recent studies, TLG was considered as a much better indicator than MTV in prognosis evaluation [17]. It is conceptual understandable that TLG gained favour. As the product of SUV\textsubscript{mean} and MTV, TLG not only reflects the tumor volume [18], but also shows the abnormal level of metabolism inside the tumor tissue. Furthermore, TLG was proved to be strongly correlated with clinical factors, which was not showed in other metabolic studies. Chong et al. [19] reported TLG was significantly correlated with CA19–9 level in patients with resected pancreatic cancer. Further proved the advanced oncologic

Table 4 Multivariate Analysis of Prognostic Factors for OS and PFS in 73 LAPC patients

| Factors                  | OS          | PFS         |
|--------------------------|-------------|-------------|
|                          | B Value     | Wald Value  | P Value | HR (95%CI) | B Value     | Wald Value  | P Value | HR (95%CI) |
| Radiotherapy dose        | −0.735      | 8.090       | 0.004   | 0.480(0.289–0.796) | −0.525      | 4.521       | 0.033   | 0.591(0.364–0.960) |
| Chemotherapy             | −0.752      | 6.698       | 0.010   | 0.471(0.267–0.833)  | −0.559      | 4.198       | 0.040   | 0.572(0.335–0.976)  |
| TLG                      | 0.763       | 8.704       | 0.003   | 2.145(1.292–3.560)  | 0.836       | 10.938      | 0.001   | 2.307(1.406–3.787)  |

Table 5 Distribution of Clinical Factors upon with/without Chemotherapy and high/low radiotherapy dose

| Clinical Factors      | Chemotherapy | P Value | Radiotherapy Dose | P Value |
|-----------------------|--------------|---------|------------------|---------|
| Age, Median           | −0.515       | 0.607   | −1.517           | 0.129   |
| Gender                | −1.299       | 0.194   | −0.633           | 0.527   |
| N Stage               | −1.205       | 0.228   | −1.062           | 0.288   |
| Serum CA19–9, Median  | −0.171       | 0.864   | −0.115           | 0.909   |
| Present of DM         | −0.789       | 0.430   | −1.498           | 0.134   |
| Longest Diameter, Median | −1.205       | 0.228   | −1.062           | 0.288   |
| Tumor Location        | −0.037       | 0.970   | −1.596           | 0.110   |
| ECOG Score            | −0.096       | 0.923   | −1.881           | 0.060   |

DM diabetes mellitus; ECOG Eastern Cooperative Oncology Group

prognostic value of TLG. Choi et al. [20] retrospectively analyzed 60 patients with LAPC and found the pre-treatment MTV value was an independent prognostic factor for both PFS and OS. At the same time, TLG was an independent prognostic indicator for PFS. In addition, the disease control rate (DCR) was significantly higher among LAPC patients with low MTV or TLG value. Similar results were found by our previously published work [11], in which 23 LAPC patients received chemo-SBRT combined therapy were included. And MTV was proven to be an independent prognostic factor for OS. In the current study, with a wider inclusion criterion and a larger group of research samples, both MTV and TLG are proved to be associated with PFS and OS by univariate analysis. Further tested by multivariate analysis, only TLG was an independent prognostic factor for OS and PFS. We divided TLG into 4 groups based on its quartile, and further analyzed the relationship between TLG and OS with Cox proportional hazards model. Although all the p values were > 0.05, the trend of higher TLG value lead to poorer prognosis could also be indicated from the analysis. The insignificant result might be related to the limited patients included in the study. Compared to our last study, the difference in analytical results may be caused by inclusion criteria. Not only LAPC patients received chemo-SBRT combined therapy were included, but also LAPC patients treated with SBRT only were enrolled in this research. Additionally, only 23 patients were analyzed in the previous study, the number was broadened to 73 patients in this study. And the difference in patient numbers may be another reason leading to the discrepant results.

As mentioned above, although a number of previous studies have discussed the prognostic value of MTV and TLG in LAPC patients, all came up with various results [16, 20]. This could be caused by different inclusion criteria, especially variable treatment options. Research carried out by Dholakia et al. [16] included 32 LAPC cases underwent SBRT, among which 27 of 32 cases were pre-treated with 1 cycle of gemcitabine-based inducing chemotherapy. In another study performed by Choi et al. [20], all 60 LAPC patients were treated with gemcitabine-based chemotherapy combined with SBRT. In our study, 73 cases of LAPC were treated with SBRT, 23 cases of which were combined with chemotherapy. Additionally, the discrepant results might also arise from unstandardized MTV delineation. The commonly used methods for MTV delineation are relative
threshold method, multiple SUV absolute threshold method and gradient threshold method. A phantom study suggested that 40–50% of SUV$_{\text{max}}$ could maximally delineate the actual tumor lesion [21]. Currently, the mainstream measurement methods of MTV include fixed SUV value, based on threshold and algorithm-based. MTV measured based on thresholds performed well in prognosis evaluation in several studies [22–24], and the method is simpler than algorithm-based. Because of tumor heterogeneity, the metabolic level of pancreatic cancer can be varied individually. When the metabolism level of pancreatic cancer is low, the fixed SUV thresholds may have a larger risk of underestimating the actual tumor volume, which will bias the results with false negative errors. Therefore, the method of MTV measurement based on threshold was applied in this study. However, if the threshold of MTV is too low, it is easy to cause an over-high background. If the threshold of MTV is too high, it may underestimate the tumor volume, and even cause partial volume effects. According to the research carried out by Dholakia et al. [25], MTV was calculated at 40% of the SUV$_{\text{max}}$ value. In addition, our previous study [11] also found that MTV assessed based on a threshold of 40% was an independent prognostic factor for LAPC. For the later researches, the standardization of SUV threshold should be improved to widen the application of FDG PET/CT volume parameters in disease prognosis.

Despite the value of TLG in the prognostic assessment of SBRT treated LAPC patients, our study also showed that chemotherapy was an independent prognostic factor for PFS and OS. With chemotherapy, the survival duration of PFS and OS could be improved, which reconfirmed the role of chemotherapy in LAPC treatment [26, 27]. To date, the CRT remains to be a recommended treatment plan for LAPC patients, though the role of traditional radiotherapy was controversial. In order to offer a better treatment option, several clinical trials tried to compare the survival rates between single chemotherapy and CRT in LAPC patients, ending up with contradictory results [26, 27]. In recent years, Cyberknife therapy has been recognized by the American Society of Clinical Oncology to have a role in LAPC treatment [3]. As a newly improved SBRT equipment, the Cyberknife has been applied for LAPC treatment, and the value has been verified by several studies, as well as in our study [4, 5, 28]. It was found that the PFS and OS of LAPC patients received a higher radiotherapy dose (> 64.4 Gy) was significantly longer than those receiving a therapeutic dose (≤64.4 Gy). Similar results were found by Gurka et al. [29]. Therefore, for LAPC patients with high pretreatment TLG, if the basic conditions and chemo-tolerance allowed, we suggested a combination treatment of chemotherapy and high radiotherapy dose improve prognosis.

There are limitations to this study. First, Considering of the defects of retrospective study, the follow-up plan was not highly standardized, which limited the robustness of PFS. In addition of censored data and selection bias. The confidence intervals in this study were not ideal, which may due to the limited number of patients limited. To get a more precised result, a randomized controlled prospective...
with a large sample size needs to be performed in the future work. Secondly, some images presented with diffuse uptake because of obstructive pancreatitis, it was difficult to clearly contour the tumor lesions, which might affect the measurement of MTV. Thus, ceCT and MRI images were used to help define tumor tissue. However, as ceCT and MRI and PET/CT scans were performed by different machines, there may be some deviation in the image matching. More effort will be paid and Co-scans could be performed in future work to improve the accuracy of tumor delineation. All patients underwent a ceCT scan or a MRI scan before radiotherapy, and the images were used to help differentiate pancreatic inflammatory from tumor.

Conclusions
The $^{18}$F-FDG PET/CT metabolic parameters MTV and TLG were significantly associated with PFS and OS. TLG, radiotherapy dose, and chemotherapy were independent prognostic indicators of PFS and OS for LAPC patients treated with SBRT.

Abbreviations
ASCO: American Society of Clinical Oncology; CA19–9: Carbohydrate antigen 19–9; CRT: Chemoradiotherapy; ECOG: Eastern cooperative oncology group; HR: Hazard ratio; LAPC: Locally advanced pancreatic cancer; MTV: Tumor metabolic volume; OS: Overall survival; OSEM: Ordered subset expectation maximization; PFS: Progression-free survival; PTV: Planning target volume; RADIOTHERAPY: Gross tumor volume; SBRT: Stereotactic body radiation therapy; TLG: Total lesion glycolysis

Acknowledgments
This work would thank the help of Dr. Xiaofei Ye from the Statistics Department of Navy Medical University and other authors in the paper writing. We confirm that all experiments were performed in accordance with relevant guidelines and regulations, and written informed consent was waived by the Institutional Review Board.

Authors’ contributions
Shengnan Ren was responsible for generating the original concept, writing an original draft, performing analysis and validation. Xiaofei Zhu provided supervision and in charge of patient data management, as well as data process and analysis. Anyu Zhang edited and interpreted data for the work. Dannni Li made substantial contributions to the whole process of this study. In addition, Changjing Zuo helped in the original concept generation and ensured that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved. Huojun Zhang helped to provide data sources and follow up information. The authors read and approved the final manuscript.

Funding
The study has received funding from the National Natural Science Foundation of China (Grant No. 81471714, 81873190) and the Starting Foundation for Young Researcher of Changhui Hospital (No. 2019QN07).

Availability of supporting data
Supporting data could be reached by contacting the corresponding authors.

Ethics approval and consent to participate
Ethical approval from the research committee of the author’s institution in accordance with the Helsinki Declaration, and participation consent was obtained.

Consent for publication
Not applicable.

Competing interest
The authors declare that they have no competing interests.

Received: 28 November 2019 Accepted: 2 March 2020
Published online: 10 March 2020
18. Foley KG, Fielding P, Lewis WG, Karran A, Chan D, Blake P, et al. Prognostic significance of novel 18F-FDG PET/CT defined tumour variables in patients with oesophageal cancer. Eur J Radiol. 2014;84(12):1069–73.

19. Chong JU, Hwang HK, Lee JH, Yun M, Kang CM, Lee WJ. Clinically determined type of 18f-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer. PLoS One. 2017;12(2):e0172606.

20. Choi HJ, Lee JW, Kang B, Song SY, Lee JD, Lee JH. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Yonsei Med. 2014;55(6):1498–506.

21. Uto F, Shiba E, Onoue S, Yoshimura H, Takada M, Tsuji Y, et al. Phantom study on radiotherapy planning using PET/CT—delineation of RADIOTHERAPY by evaluating SUV. J Radiat Res. 2010;51(2):157–64.

22. Im HJ, Bradshaw T, Solayyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging. 2018;52:5–15.

23. Fan B, Fan P, Kong L, Sun X, Zhao S, Sun X, et al. 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma. Oncotarget. 2017;8:34498–506.

24. Mazzola R, Fersino S, Alongi P, Di Paola G, Gregucci F, Aiello D, et al. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT. Br J Radiol. 2018;91:20180058.

25. Xu M, Wang L, Ouyang M, Lin J, Wang L, Zheng X, et al. Prediction of lymph node metastasis by PET/CT metabolic parameters in patients with esophageal squamous cell carcinoma. Nucl Med Commun. 2019;49:333–9.

26. Neoptolemos JP, Stocken DD, Smith CT, Bassi C, Ghanem P, Owen E, et al. Adjuvant S-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 2009;100(2):246–50.

27. Huguet F, Andrè T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25(3):326–31.

28. Jumeau R, Delouya G, Roberge D, Donath D, Béliveau-Nadeau D, Campeau MP. Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: a single center experience. Dig Liver Dis. 2018;50(4):396–400.

29. Gurka MK, Collins SP, Stack R, Tse G, Charabaty A, Ley L, et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol. 2013;8(1):44.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.